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Objective. To evaluate the clinical results achievable using stereotactic radiosurgery, the principal alternative to microsurgical
resection to treat acoustic neuromas. The goals of radiosurgery are, long-term prevention of tumor growth, maintenance of
neurologic function, and prevention of new neurologic deﬁcits.
Methods. We studied thirty-six patients who had undergone radiosurgery under the guidance of magnetic resonance, at Cruces
University Hospital, between 2009 and 2012. Outcomes were determined through the use of serial imaging studies, clinical
evaluations, the need for surgical intervention, and a survey of patients. We included only patients who completed at least one
clinical-radiological evaluation. Radiographic tumor progression was strictly deﬁned as any temporary or sustained increase in
tumor diameter of at least 1 mm in two dimensions or 2 mm in any direction.
Results. Seventy-ﬁve percent of patients were women. Median age was 63 years (range 33–84). The tumor was on the left side in
the 63.89% of cases; had a mixed localization in the 61.11%. Previous resection performed in 4 patients (11.11%). Fifty percent
of patients were treated with monofraction (12Gy), median maximal tumor diameter was 12 mm (range 7.5–18), median PTV
volume 0.92 cc (range 0.17–3.16). Eighteen patients were treated with a median dose of 50Gy (range 18–54), median maximal
tumor diameter 23.5 mm (range 5–55), median PTV volume 5.97 cc (range 0.7–50.97) prescribed to the 98% of PTV, and delivered in
3–25 fractions. Median follow-up period was 15.5 months (range 4–34). The crude tumor control rate was 91.66%. 92% of patients
retained useful hearing, and 8 had minor neurological complications, such as worsening of initial symptoms or grade 1 cranial
neuropathy.
Conclusions. Long-term follow-up of our data is needed, but our preliminary results conﬁrmed the excellent tumor control
reported, hearing preservation, and acceptable toxicity.
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Background. Radiosurgery is commonly used for the treatment of intracranial pathology and skull base as metastases, menin-
giomas, neurinomas and MAV. This study provides a retrospective evaluation of patients with this type of malignancy and benign
treated with radiosurgery at our institution.
Objectives. Provide details of the results of a single institutional experience with SRS.
Methods. We present 312 patients treated with SRS between 2005 and 2012. Among them, 152 were treated (49%) patients with
brain metastases with a maximum of 4 per patient, 59 (19%) patients with acoustic neuroma, 56 (18%) meningiomas, 20 (6%)
AVMs, and 20 (6%) patients with less common diseases.
Results. Of all the patients treated with brain metastases, 20% are still alive. Regarding the treated neurinomas exhibit stable
disease, 84% of them, just as meningiomas and cerebral AVM whit minimal long term toxicity.
Conclusions. Given the results we can say that the SRS is a safe treatment technique for brain metastases in number less than 4,
meningiomas, neurinomas and MAV.
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Introduction. The treatment of malignant glioma consists in complete surgery or broadest possible, followed by radiation on the
previous location of the removed tumor and, in many cases, with concomitant and adjuvant chemotherapy. These tumors have a
high recurrence rate despite receiving appropriate treatment, being proportional to histologic grade. Once you see a recurrence,
reoperation and change line chemotherapy are usual. Due to the advancement of radiosurgery techniques and greater availability,
is being increasingly used for the treatment of small size recurrence, or to treat some rest after surgery.
Objective. Descriptive study of patients suffering from malignant gliomas treated with radiosurgery in the Carlos Haya Hospital.
